Delivra Health Brands to Hold Conference Call to Discuss Results for the Second Quarter of Fiscal 2025
Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) has announced it will release its financial results for Q2 fiscal 2025, covering the three and six months ended December 31, 2024. The company will host a conference call on Thursday, February 27, 2025, at 11:00 a.m. EST to discuss these results.
The conference call will feature a Q&A session led by President and CEO Gord Davey and CFO Jack Tasse. Interested parties can join via toll-free number 1-833-752-2525 (Canada/USA) or +1-647-846-2674 (International). Participants are advised to dial in 10 minutes before the scheduled start time. A replay will be available on the company's investor page following the call.
Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) ha annunciato che rilascerà i suoi risultati finanziari per il secondo trimestre dell'esercizio fiscale 2025, coprendo i tre e sei mesi terminati il 31 dicembre 2024. L'azienda ospiterà una conferenza telefonica giovedì 27 febbraio 2025, alle 11:00 EST per discutere di questi risultati.
La conferenza telefonica includerà una sessione di domande e risposte guidata dal Presidente e CEO Gord Davey e dal CFO Jack Tasse. Le parti interessate possono partecipare tramite il numero verde 1-833-752-2525 (Canada/USA) o +1-647-846-2674 (Internazionale). Si consiglia ai partecipanti di chiamare 10 minuti prima dell'orario di inizio programmato. Una registrazione sarà disponibile sulla pagina per gli investitori dell'azienda dopo la chiamata.
Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) ha anunciado que publicará sus resultados financieros para el segundo trimestre del ejercicio fiscal 2025, cubriendo los tres y seis meses finalizados el 31 de diciembre de 2024. La empresa llevará a cabo una conferencia telefónica el jueves 27 de febrero de 2025, a las 11:00 a.m. EST para discutir estos resultados.
La conferencia telefónica contará con una sesión de preguntas y respuestas dirigida por el Presidente y CEO Gord Davey y el CFO Jack Tasse. Las partes interesadas pueden unirse a través del número gratuito 1-833-752-2525 (Canadá/EE.UU.) o +1-647-846-2674 (Internacional). Se aconseja a los participantes que llamen 10 minutos antes de la hora de inicio programada. Una repetición estará disponible en la página de inversores de la empresa después de la llamada.
Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF)는 2024년 12월 31일로 종료된 3개월 및 6개월을 포함한 2025 회계연도 2분기 재무 결과를 발표할 것이라고 발표했습니다. 회사는 2025년 2월 27일 목요일 오전 11시 EST에 이 결과를 논의하기 위한 컨퍼런스 콜을 개최할 예정입니다.
컨퍼런스 콜에는 회장 겸 CEO인 Gord Davey와 CFO인 Jack Tasse가 이끄는 Q&A 세션이 포함될 것입니다. 관심 있는 분들은 무료 전화번호 1-833-752-2525(캐나다/미국) 또는 +1-647-846-2674(국제)로 참여할 수 있습니다. 참가자는 예정된 시작 시간 10분 전에 전화하는 것이 좋습니다. 통화 후 회사의 투자자 페이지에서 다시 듣기가 가능합니다.
Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) a annoncé qu'elle publiera ses résultats financiers pour le deuxième trimestre de l'exercice fiscal 2025, couvrant les trois et six mois se terminant le 31 décembre 2024. L'entreprise tiendra une conférence téléphonique le jeudi 27 février 2025, à 11h00 EST pour discuter de ces résultats.
La conférence téléphonique comprendra une session de questions-réponses dirigée par le Président et PDG Gord Davey et le CFO Jack Tasse. Les parties intéressées peuvent se joindre via le numéro sans frais 1-833-752-2525 (Canada/États-Unis) ou +1-647-846-2674 (International). Il est conseillé aux participants de composer le numéro 10 minutes avant l'heure de début prévue. Un enregistrement sera disponible sur la page des investisseurs de l'entreprise après l'appel.
Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) hat angekündigt, dass es seine finanziellen Ergebnisse für das zweite Quartal des Geschäftsjahres 2025 veröffentlichen wird, die die drei und sechs Monate bis zum 31. Dezember 2024 abdecken. Das Unternehmen wird am Donnerstag, den 27. Februar 2025, um 11:00 Uhr EST eine Telefonkonferenz abhalten, um diese Ergebnisse zu besprechen.
Die Telefonkonferenz wird eine Q&A-Sitzung unter der Leitung von Präsident und CEO Gord Davey sowie CFO Jack Tasse umfassen. Interessierte Parteien können über die gebührenfreie Nummer 1-833-752-2525 (Kanada/USA) oder +1-647-846-2674 (international) teilnehmen. Den Teilnehmern wird geraten, 10 Minuten vor der geplanten Startzeit anzurufen. Eine Wiederholung wird nach dem Anruf auf der Investorenseite des Unternehmens verfügbar sein.
- None.
- None.
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2025) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or the "Company"), a consumer packaged goods leader uniquely positioned in the health and wellness sector, is pleased to announce it will report its financial results for the three and six months ended December 31, 2024, on Thursday, February 27, 2025.
Conference Call Details
The Company will host a conference call on Thursday, February 27, 2025, at 11:00 a.m. (EST) / 8:00 a.m. (PST) to discuss the financial results for the three and six months ended December 31, 2024. Gord Davey, President and Chief Executive Officer, and Jack Tasse, Chief Financial Officer of the Company will be conducting a question-and-answer session following management's prepared remarks.
Participant Dial-In Numbers:
All interested parties can join the conference call by dialing: 1-833-752-2525 (Canada/USA Toll Free) or +1-647-846-2674 (International Toll). Please dial in 10 minutes prior to the scheduled start time and ask to join the Delivra Health Brands call. A replay of the call will be available on the Company's investor page by the end of the business day on Thursday, February 27, 2025.
About Delivra Health Brands Inc.
Helping people take control of their health with alternative wellness solutions is what energizes the Delivra Health team! The Delivra Health portfolio features innovative brands like Dream Water® and LivRelief™, which deliver relief from common everyday issues like chronic pain, anxiety, and sleeplessness. Delivra Health products have allowed millions of customers to reclaim their mobility, energy, and in turn, quality of life. The websites of the Company's two subsidiaries are Dream Water® and LivReliefTM. For more information, please visit www.delivrahealthbrands.com.
Cautionary Note Regarding Forward-Looking Statements
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements include, among other things, statements with respect to the timing of reporting the Company's financial results for the three and six months ended December 31, 2024, and the timing of the conference call.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the cannabis markets where the Company operates; changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; employee relations and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution, and sale of cannabis and cannabis-related products in the markets where the Company operates. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Additional information regarding this and other risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form dated March 2, 2021, and under the heading "Risks and Uncertainties" in the Company's management's discussion and analysis dated November 25, 2024, for the three months ended September 30, 2024, filed under the Company's profile on SEDAR+ at www.sedarplus.ca.
Neither TSX Venture Exchange or its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
Investor Relations:
Jack Tasse
Chief Financial Officer
IR@delivrahealth.com
1-877-915-7934
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/242200
FAQ
When will Delivra Health Brands (DHBUF) release its Q2 2025 financial results?
What time is Delivra Health Brands' (DHBUF) Q2 2025 earnings call?
How can investors join Delivra Health Brands' (DHBUF) Q2 2025 earnings call?
Where can investors find the replay of Delivra Health Brands' (DHBUF) Q2 2025 earnings call?
